A leader in motion management technology, Calypso now introduces the first real-time solution that gates on the internal target versus external surrogates. Dynamic Edge™ Gating automatically signals the linac to hold the beam when the target moves outside a patient-specific motion threshold safeguarding normal tissue from unintended radiation. In combination with Calypso’s clinically proven real-time tracking, Dynamic Edge Gating joins the Calypso family of products designed to reduce treatment margins and improve outcomes for prostate radiotherapy patients.
Calypso’s technology provides the knowledge that prostate motion is accurately and precisely tracked to allow clinicians to confidently deliver the larger radiation doses per fraction called for by stereotactic body radiation therapy (SBRT) protocols. Scientific literature suggests these larger doses per fraction may provide a radiobiological advantage over the more conventional approach which uses a smaller dose per fraction and a larger number of fractions. Combining Calypso’s real-time tracking with SBRT creates a treatment approach that allows patients to maintain their quality of life while spending significantly less time away from work.
The prospective, multi-site study, entitled “Assessing the Impact of Margin Reduction (AIM),” is the first outcome-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.” The findings of the AIM clinical study, which are published in Urology (The GOLD JOURNAL), demonstrate that the use of the Calypso® System during high-dose external beam radiation for prostate cancer resulted in a significant reduction in rectal and urinary treatment-related side effects.
The Calypso® System delivers precision and accuracy—continuously and in real time—enabling radiation oncology clinicians to keep the target in the path of the radiation beam at all times. By detecting the slightest tumor movement—and enabling the patient to be repositioned if necessary—the Calypso System helps clinicians deliver maximum radiation directly to the tumor while avoiding healthy surrounding tissues and organs.
Clinical research demonstrates that tracking prostate motion during radiation therapy allows a reduction in the planning target volume (PTV), resulting in fewer patient-reported prostate radiation side effects. Summaries of our clinical research highlights, clinical presentations and other materials have been assembled to demonstrate how to incorporate real-time tracking into your treatment regimen and to increase the quality of life for your patients.
Calypso's robust clinical biography includes peer-reviewed articles and abstracts that have been presented at major medical meetings throughout the world.
A library of white papers and clinical case studies provides a range of clinical applications utilizing the Calypso System and describes unique benefits your practice or care center may offer.
As radiation oncologists, it's always our desire to maximize cure rate and minimize complications. It's all about treating with tight margins and knowing precisely where that target is located.”
Timothy P. Mate, M.D.
Swedish Medical Center